Takeda Highlights Rare Neurological Disorder Programs In Wave 1

Takeda Pharmaceutical Co. Ltd. sees neuroscience as an important part of its Wave 1 research and development pipeline plans, but the company has pivoted away from psychiatry to focus on rare neurological disorders. During a second investor briefing on its Wave 1 pipeline on 6 April, the pharma detailed why it thinks soticlestat for two rare epileptic disorders and its orexin agonist program for narcolepsy can bring needed improvements to patients not well served by current therapies.

In December, Takeda presented an initial look at the Wave 1 candidates – 12 new molecular entities all expected to launch by the end of fiscal 2024 (the Japanese pharma’s fiscal year ends on 31 March) and predicted they would help drive revenue growth to JPY5,000bn (about $48bn) by the end of fiscal 2030